Alkermes plc. Deferred Federal, State and Local, Tax Expense (Benefit)
Alkermes plc. (ALKS) reported Deferred Federal, State and Local, Tax Expense (Benefit) of $28.62 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit · last filed 2026-02-25
- Alkermes plc. deferred federal, state and local, tax expense (benefit) for fiscal 2025 was $28.62M, a 53.68% decline from fiscal 2024.
- Alkermes plc. deferred federal, state and local, tax expense (benefit) for fiscal 2024 was $61.78M.
- Alkermes plc. deferred federal, state and local, tax expense (benefit) for fiscal 2023 was -$107.06M.
| Period end | Deferred Federal, State and Local, Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $28.62M 10-K · filed 2026-02-25 |
| 2024-12-31 | $61.78M 10-K · filed 2026-02-25 |
| 2023-12-31 | -$107.06M 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |